Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
Login
MSAR Home
→
MSA University Academic Research
→
Research Papers, Articles and Books Chapters.
→
Faculty Of Pharmacy Research Paper
→
View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
Essa, A
;
Mohamed Ibraheem, K.I
;
Elimam, H
;
Elnaidany, N
;
Shehab-Eldeen, S
;
Abdu Allah, A.M
;
Sabry, A
;
Abbasy, M
;
Nada, A
Full Text link:
https://t.ly/y6K20
Date issued:
2020
Scientific Journal Rankings:
Click Here
Doi:
https://doi.org/10.1155/2020/1632959
Publisher:
Hindawi Limited
Series Info:
Canadian Journal of Gastroenterology and Hepatology;Volume 2020, 2020, Article number 1632959
Type:
Article
Keywords:
university of Sofosbuvi , Egyptian Patients , HCV-Positive , Lipocalin (NGAL) , Serum Neutrophil
Abstract:
Background. Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGAL) has been proven as a predictor of renal tubular injury. Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen. Methods. This prospective study included 87 Egyptian patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks. Serum NGAL was measured before and at the end of treatment (EOT). Analysis of NGAL and estimated glomerular filtration rate (eGFR) evolution was done. Results. Our results showed a statistically significant decrease in serum NGAL (P=0.02) with a nonsignificant reduction in eGFR (P=0.06). Moreover, changes in serum NGAL levels (baseline compared to EOT) in patients ranked by KDIGO-CKD classification showed a significant decrease in stages 1 and 2 (P=0.14 and 0.034, respectively) and a nonsignificant decrease in stage 3 (P=0.25). Also, eGFR changes after treatment in patients ranked by the same classifications showed a nonsignificant reduction in all stages (P>0.05). Conclusions. Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection. © 2020 Ali Nada et al.
Description:
MSA Google Scholar
SCOPUS
Show full item record
Files in this item
Name:
avatar_scholar_256.png
Size:
6.309Kb
Format:
PNG image
View/
Open
Name:
1632959.pdf
Size:
1.303Mb
Format:
PDF
View/
Open
This item appears in the following Collection(s)
Faculty Of Pharmacy Research Paper
[1121]
Search MSAR
Search MSAR
This Collection
Advanced Search
Browse
All of DSpace
Communities & Collections
By Issue Date
Authors
Titles
Subjects
This Collection
By Issue Date
Authors
Titles
Subjects
My Account
Login
Register